Patients who received obinutuzumab were less likely to experience a renal-related event or death, compared with those who received placebo. The Food and Drug Administration (FDA) has approved Gazyva ® ...

This review outlines the emerging role of Interleukin-26 in autoimmune disease biology and describes a possible diagnostic and therapeutic signal for patient monitoring and future stratification.

CHICAGO -- People who died with systemic lupus erythematosus (SLE) were far more likely than car crash victims to have severe cardiac abnormalities such as heart enlargement, valvulopathy, and ...

Yale School of Medicine (YSM) researchers have made key breakthroughs in understanding how to treat fibrotic diseases such as ...

The hallmarks of Sjögren's disease are sicca symptoms and dysfunction of the salivary and lacrimal glands, Reed and ...

Scientists at Gladstone Institutes and UC San Francisco (UCSF) have mapped the intricate network of genetic switches that ...

Sjögren’s Disease (SD) In October 2025, Vor Bio’s and its collaborator, RemeGen Co., Ltd, reported positive top-line Phase 3 results from the study of telitacicept in Sjögren’s disease in China. The ...

An estimated 50% of patients with SLE will develop lupus nephritis in their lifetime, with people of African descent more ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 ...

Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gr ...

New deal builds on the success of a longstanding partnership in retinal health and the potential of CDR-Life's unique antibody fragment-based platform   Agreement provides potential for up to approx.